Fenitrothion: toxicokinetics and toxicologic evaluation in human volunteers. by Meaklim, Jean et al.
Environmental Health Perspectives • VOLUME 111 | NUMBER 3 | March 2003 305
Fenitrothion: Toxicokinetics and Toxicologic Evaluation in Human Volunteers
Jean Meaklim,1 Jinming Yang,1 Olaf H. Drummer,2 Sheila Killalea,1 Voula Staikos,2 Soumela Horomidis,2
David Rutherford,3 Lisa L. Ioannides-Demos,1 Stephen Lim,1 Allan J. McLean,4 and John J. McNeil1
1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; 2Victorian Institute of Forensic
Medicine and the Department of Forensic Medicine, Monash University, Melbourne, Australia; 3Pathology Department, Alfred Hospital,
Melbourne, Australia; 4Clinical Pharmacology Department, Alfred Hospital, Melbourne, Australia
Fenitrothion is a broad spectrum organic
phosphorothiate (organophosphate) insecti-
cide used to protect fruit, vegetables, and
grain crops. In Australia it has been widely
used to protect stored grain, whereas in many
tropical countries it has found extensive use
as a residual spray in homes for malaria con-
trol. Its popularity stems from the high
potency and broad spectrum of its insecticide
action, its chemical stability, and its low
acute mammalian toxicity.
Because of its widespread use on stored
grain, fenitrothion is the most common
insecticide residue in Australian food. Surveys
undertaken during the 1980s showed the
daily intake of fenitrothion among individu-
als consuming reasonable quantities of cere-
als, bread, and other grain-based foods could
come close to the upper end of the Food and
Agriculture Organization of the United
Nations (FAO)/World Health Organization
(WHO) acceptable daily intake (ADI) of
0.0–0.005 mg/kg body weight/day (1).
During the 1990s, however, residue levels
have declined, and the 1996 Australian
Market Basket survey suggested the average
intake among young children was approxi-
mately 12% of the ADI, whereas that in
adults was approximately 4% of the ADI (2).
The ADI for a chemical is the highest level
of consumption believed to cause no adverse
health effects over a lifetime of exposure. For
fenitrothion, it is based on studies in rodents
that have established a no-observed adverse
effect level to which a safety margin is applied
to account for possible interspecies differences
in toxicity between humans and animals.
Because of the widespread human exposure to
fenitrothion, it is important to have more direct
evidence of the agent’s kinetic behavior and the
relationship between plasma level and toxicity.
This study was established to examine the
kinetics of fenitrothion in humans after single
and repeated dosing and to relate the observed
plasma levels to suppression of plasma and red
blood cell cholinesterase levels. The subjects
were selected from volunteers chosen
because of their high level understanding of
toxicology and selection was approved by
the Ethics Committee at Monash University
in Australia. All subjects underwent careful
hematologic and biochemical monitoring.
Materials and Methods
Pilot study. In an initial pilot study, three
adult males (mean age 45 years) ingested sin-
gle doses of fenitrothion at dose levels of
0.06, 0.18, and 0.36 mg/kg (12, 36, and 72 ×
ADI, respectively). Doses were separated by
at least 2 weeks. Blood samples were collected
at intervals over the subsequent 4 days for the
analysis of fenitrothion, fenitrooxon, and
plasma cholinesterase levels. Urine was col-
lected for 2 days, and biochemical and hema-
tologic monitoring was also performed during
the course of the study.
Main study design. Twelve adult volunteers
received each of two dose levels of fenitrothion,
formulated as capsules and taken with food
over 4 days. Dose level 1 was 0.18 mg/kg/day
(36 × ADI) administered as two divided
doses given at 12-hr intervals (morning and
evening). Dose level 2 was 0.36 mg/kg/day
(72 × ADI). The two dosing periods were
separated by at least 2 weeks, and up to 5
months with some participants. The study
commenced in November 1994 and was
completed by May 1995.
Participants. Twelve healthy adult volun-
teers were recruited from among the scientiﬁc
and medical communities in Melbourne,
Australia. Eight were male and four were
female, with ages ranging from 23 to 50 years
(mean 33 years). Before commencing the
study, participants underwent a medical
examination and biochemical screens (includ-
ing plasma cholinesterase levels) to confirm
suitability for inclusion. Volunteers were
required to be otherwise healthy and have
normal baseline blood tests for hematology,
organ function, biochemistry profile, and
cholinesterase activity.
Protocol. All clinical procedures were con-
ducted in The Alfred Hospital, Department
of Clinical Pharmacology in Melbourne. After
an overnight fast, individuals received a single
dose of fenitrothion (formulated as a capsule
and given with food) equivalent to one-half
the daily dose. Blood samples were drawn pre-
dose for measurement of fenitrothion and its
metabolites and at 1, 2, 3, 4, 6, 8, 10, and 12
hr after the ﬁrst dose on day 1 and at similar
times after the morning dose on day 4. Blood
was also drawn predose and at 4 and 8 hr after
dosing for measurement of whole blood and
plasma cholinesterase levels. Urine was col-
lected over a 24-hr period on days 1 and 4.
Subjects were observed in the department
for 12 hr on days 1 and 4, with regular blood
pressure measurement and regular question-
ing about the presence of adverse effects.
Biochemical and hematologic parameters
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An unblinded crossover study of fenitrothion 0.18 mg/kg/day [36 times the acceptable daily
intake (ADI)] and 0.36 mg/kg/day (72 × ADI) administered as two daily divided doses for 4 days
in 12 human volunteers was designed and undertaken after results from a pilot study. On days 1
and 4, blood and urine samples were collected for analysis of fenitrothion and its major metabo-
lites, as well as plasma and red blood cell cholinesterase activities, and biochemistry and hematol-
ogy examination. Pharmacokinetic parameters could only be determined at the higher dosage, as
there were insufﬁcient measurable fenitrothion blood levels at the lower dosage and the fenitro-
oxone metabolite could not be measured. There was a wide range of interindividual variability in
blood levels, with peak levels achieved between 1 and 4 hr and a half-life for fenitrothion of
0.8–4.5 hr. Although based on the half-life, steady-state levels should have been achieved; the area
under the curve (AUC)0–12 hr to AUC0–∞ ratio of 1:3 suggested accumulation of fenitrothion.
There was no signiﬁcant change in plasma or red blood cell cholinesterase activity with repeated
dosing at either dosage level of fenitrothion, and there were no signiﬁcant abnormalities detected
on biochemical or hematologic monitoring. Key words: fenitrothion, pesticides, pharmacokinetics,
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Research | Articleswere measured predose on day 1 and 3 days
after the completion of each dosing period.
On days 2 and 3 of each dosing period, the
study coordinator or study nurse contacted
participants daily to deliver capsules and to
ensure compliance with the study protocol.
Formulation of fenitrothion capsules.
Fenitrothion capsules were manufactured in
Melbourne by The Institute of Drug
Technology from technical-grade fenitrothion
supplied by Sumitomo Chemical Company
Ltd. (Osaka, Japan). Capsules were formu-
lated in accordance with the Code of Good
Manufacturing Practice (3) and kept refriger-
ated prior to dispensing.
Analysis. Fenitrothion was extracted from
acidified whole blood with butyl chloride.
After evaporation of the solvent, the reconsti-
tuted extract was chromatographed on a BP-5
capillary column (J&W Scientiﬁc, Melbourne,
Australia) and the response measured with
a nitrogenphosphorus detector (Agilent
Technologies, Melbourne, Australia). Diazinon
was used as an internal standard to correct for
variation in recovery. Detection limits were
0.1–0.4 ng/mL, and assay precision was 17% at
0.3 ng/mL, 13% at 0.6 ng/mL, and 5.8% at
1.0 ng/mL. Accuracy at all concentrations was
± 20%, and reproducibility of fenitrothion at
these concentrations (n = 17–20) was 16, 7.5,
and 8.6%, respectively. Fenitrothion was stable
when stored at –20°C over a 6-month period.
The levels of the metabolite 3-methyl-4-
nitrophenol (MNP) in urine were measured
after hydrolysis of the urine samples with 8
M HCl to convert conjugated MNP to free
MNP. MNP was then extracted with butyl
chloride and acetylated with acetic anhy-
dride, and the derivative was extracted with
butyl chloride. The reconstituted solvent was
chromatographed on a 15-m BP-5 capillary
column using splitless injection and a nitro-
gen-phosphorus detector. Pentobarbitone
was used as an internal standard.
The detection limit of this method from 1
mL urine was 0.25 mg/L, although some
specimens had a slightly higher limit because
of sample volume and small background
interferences. Intraassay precision and interas-
say reproducibility were 6% at a concentration
of 8.0 mg/L.
Plasma and red blood cell cholinesterase
levels were determined by the Michel method
(4), which measures the change in pH of a
blood mixture over time (units in ∆pH/hr).
Ethics. The research protocol was approved
by the Monash University Ethics Committee.
Participants were provided with a Plain
Language Statement plus a complete study pro-
tocol. They were recruited from a group with
sufﬁcient scientiﬁc knowledge to evaluate the
toxicologic issues and risks of the study and
were provided with the option of discussing
these with an independent physician. All 
participants gave written informed consent. 
Pharmacokinetic analysis. The plasma
concentration time data were entered into
WinNonlin (Version 3.0; Pharsight
Corporation, Mountain View, California,
USA) to calculate the time to achieve
maximum concentration (Tmax), the maxi-
mum fenitrothion concentration (Cmax), the
half-life (t1/2), and the area under the curve
(AUC). To calculate AUC0–∞ when results
for plasma samples were not detectable, half
the not-detectable value was entered for the
ﬁrst value and zero for subsequent values.
Results
Pilot study. No significant symptoms or
adverse effects were observed among the vol-
unteer participants, and cholinesterase levels
were not suppressed below 70% of predose
levels in any subject. Only limited informa-
tion was available on plasma fenitrothion or
its oxon metabolite because of difficulties
experienced with the assay development. The
available data indicated the half-life of feni-
trothion and its oxon metabolite were of the
order of 3–6 hr, and the high urinary recov-
ery of MNP suggested there were unlikely to
be substantial levels of other metabolites pre-
sent in humans. It was expected that steady-
state levels of fenitrothion and its metabolites
would be achieved after relatively brief expo-
sure to these compounds.
Main study. Fenitrothion levels. Whole-
blood concentrations of fenitrothion on days 1
and 4 after each of the two dosing schedules
are shown in Tables 1 and 2. As there were
insufﬁcient measurable fenitrothion blood lev-
els at the lower dose, the mean blood concen-
tration–time data are presented only for the
higher dose (Figure 1). Principal toxicokinetic
parameters are summarized in Table 3. 
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Table 1. Fenitrothion plasma concentrations (ng/mL): dose 1 (0.18 mg/kg/day fenitrothion).
Time (hours postdose)
Subject 0 0.5 1 2 3 4 6 8 10 12 D/L
Day 1
001 ab a a a aaaaa 0.10
002 a 0.59 1.08 0.55 0.44 aaaaa 0.10
003 ab a a a aaaaa 0.20
004 ab 0.12 1.12 0.88 0.78 b 0.31 aa 0.10
005 ab 0.54 aaaaaaa 0.20
006 a 0.57 0.74 0.42 a aaaaa 0.20
007 ab a 0.42 a 0.87 0.33 aaa 0.40
008 ab a a a aaaaa 0.10
009 ab a a a aaaaa 0.20
010 ab 0.88 0.24 a aaaaa 0.10
011 ab 1.30 aaaaaaa 0.20
012 ab 0.77 a 0.52 aaaaa 0.20
Day 4
001 1.42 b 2.10 0.66 0.54 0.40 0.39 0.31 aa 0.10
002 ab a 0.32 a aaaaa 0.10
003 ab 0.20 aaaaaaa 0.20
004 1.48 b 2.97 2.89 2.20 2.90 1.00 0.71 0.48 0.36 0.10
005 ab 0.86 0.32 0.78 0.50 aaaa 0.20
006 ab 0.35 0.48 0.43 aaaaa 0.20
007 0.42 b 1.02 1.30 0.57 0.51 0.55 aaa 0.40
008 0.14 b 0.58 0.24 0.11 0.12 aaaa 0.10
009 ab a a a aaaaa 0.20
010 ab 0.48 1.16 0.33 0.24 aaaa 0.10
011 ab a a a aaaaa 0.20
012 ab 1.04 0.43 0.54 0.62 0.38 0.25 aa 0.20
D/L, detection limit of assay. 
aNot detected. bNo sample was obtained.Fenitrothion concentrations showed high
interindividual variation, with four subjects
having all levels below the limit of detection
after the ﬁrst day of the lower doses, and two
others having no identifiable levels with the
lower dose on day 4. All subjects had
detectable levels with the higher dose on day
1 and day 4, though five subjects had only
one to two detectable levels after the first
dose. Fenitrothion was cleared and metabo-
lized from the blood too fast to obtain valid
concentrations in a sufﬁcient number of vol-
unteers at the lower dose; therefore, valid cal-
culation of kinetic parameters was possible
only at the highest dose.
The agent was absorbed rapidly, with
peak blood levels generally achieved 1–4 hr
after dosing. The half-life of the parent sub-
stance ranged from 0.8 to 4.5 hr. Although
we could not accurately determine the
AUC0–12 hr on day 4 for the lower dose and
hence the ratio of AUC0–12 hr for the two
dose levels, the concentration–time data indi-
cate a dose-dependent increase in blood con-
centrations within this dose range. For the
higher dose, the ratio of AUC0–12 hr on day
4/AUC0–∞ on day 1 was approximately 1:3,
suggesting accumulation of the parent sub-
stance; however, the high degree of inter-
individual variability makes these comparisons
relatively imprecise.
The fenitrooxon metabolite appeared
to co-elute with a large caffeine peak,
which prevented determination of its blood
concentrations.
Urine 3-methyl-4-nitrophenol. MNP was
detected in all but one of the 24-hr urine
specimens analyzed (Table 4). After adjusting
for the molar equivalent of MNP to feni-
trothion, the MNP excretion corresponded to
83 and 67% of the total fenitrothion dose
consumed on days 1 and 4 of the lower dose,
and 97 and 76% of that consumed on days 1
and 4 of the higher dose, respectively.
Cholinesterase level. Plasma and red cell
cholinesterase activity recorded during the
study were all within the normal range quoted
for the healthy adult exposed population (i.e.,
0.60–1.10 ∆pH/hr in red cells, 0.62–2.0
∆pH/hr in plasma). No statistically signiﬁcant
trends were observed in mean plasma or red
blood cholinesterase levels. There were no
individual cases where cholinesterase activity
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Table 2. Fenitrothion plasma concentrations (ng/mL): dose 2 (0.36 mg/kg/day fenitrothion).
Time (hours postdose)
Subject 0 0.5 1 2 3 4 6 8 10 12 16 24 D/L
Day 1
001 aaa 0.89 0.30 0.20 aa aa 0.59 a 0.20
002 a 1.13 1.36 0.82 0.35 0.70 a 0.22 aa 2.05 0.35 0.10
003 aaa a a 0.43 aa aa 0.42 a 0.40
004 a 16.10 15.28 5.15 1.82 1.16 1.07 0.67 0.31 0.47 2.32 0.91 0.10
005 a 0.33 0.85 0.60 1.46 0.68 aa aa 0.27 a 0.20
006 aa 0.40 0.62 aaa aa a 0.40 a 0.20
007 a 0.24 0.33 1.30 0.71 0.53 0.47 0.28 0.26 a 1.79 0.34 0.10
008 0.34 0.13 1.45 1.70 1.78 1.20 0.40 0.44 0.39 0.95 3.70 0.56 0.20
009 a 0.22 0.17 0.72 0.56 0.58 0.31 0.18 aa 0.54 0.17 0.10
010 a 0.37 0.17 aaaa a 0.55 aa a 0.10
011 aaa a 0.62 aa aaa 0.61 a 0.40
012 aaa a a 0.28 aa aa 0.50 a 0.20
Day 4
001 a 0.29 1.43 4.44 2.75 2.00 0.71 0.32 0.42 aa a 0.20
002 0.24 1.05 16.40 3.66 1.82 1.36 1.90 0.82 0.35 0.28 0.19 0.22 0.10
003 0.52 1.15 1.30 2.08 1.58 2.50 1.08 1.40 1.04 0.53 0.51 0.45 0.40
004 1.58 b 22.68 10.13 7.64 6.97 2.82 2.24 1.99 1.66 1.74 1.07 0.10
005 0.34 6.30 5.70 6.20 7.51 2.37 a 0.88 aa 0.34 a 0.20
006 a 6.44 10.24 4.31 1.96 1.18 0.73 aa 0.62 aa 0.20
007 0.51 1.17 1.30 3.60 1.44 0.96 2.28 1.37 0.89 0.96 0.65 0.39 0.10
008 0.80 3.22 23.68 8.26 5.61 3.61 1.86 1.61 1.61 1.36 0.83 0.52 0.20
009 a 4.69 4.15 1.96 1.23 0.56 0.22 aa a a a 0.10
010 a 1.24 1.61 0.12 aaa aaa aa 0.10
011 aaa 1.15 0.56 0.65 aa aa aa 0.40
012 0.44 0.96 3.51 2.34 2.66 1.49 aa 0.49 aa a 0.20
For calculating the means, half the D/L value was assigned for ﬁrst value D/L level, then zero for subsequent values. 
aNot detected. bNo sample was obtained.
Figure 1. Fenitrothion plasma concentrations (mean, standard error) after 0.36 mg/kg/day (dose 2). The rise
in fenitrothion concentration at 16 hr postdose on dose 2 day 1 is due to administration of the evening dose
at 12 hr postdose; this measurement reﬂects fenitrothion levels 16 hr after the initial (morning) dose plus
4 hr after the evening dose.
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Dose 2 day 1
Dose 2 day 4was depressed in a clinically signiﬁcant fashion
(i.e., more than 25% depression from base-
line). The largest decrease in red blood cell
cholinesterase activity from baseline was 17%
during dose 1 and 12% during dose 2. Most
subjects showed less than a 10% decrease in
red blood cell cholinesterase activity. Changes
in plasma cholinesterase activity were variable,
with subjects demonstrating an increase,
decrease, or no effect after fenitrothion dosing.
Toxicity monitoring. No clinically signiﬁ-
cant changes were noticed in blood pressure or
pulse rate. No abnormalities were observed
among the individual hematologic and bio-
chemical parameters monitored, and no trends
were observed in mean values. Few symptoms
were observed apart from one subject in whom
specific questioning elicited a report of mild
sweating and colic that did not affect normal
physical functioning and were not accompa-
nied by alterations in cholinesterase levels.
Similar but even milder symptoms were pre-
sent during the second dosage and resolved
after completion of the study.
Discussion
Short-term studies in rats and dogs have
shown that depression of plasma cholinesterase
is the most sensitive indicator of fenitrothion
toxicity. No-effect levels based on plasma
cholinesterase depression have been established
in rats (0.25 mg/kg body weight) and in dogs
(0.3 mg/kg body weight) (5). Application of a
100-fold safety margin has led to a human
ADI of 0.003 mg/kg body weight/day. Until
the early 1990s, human exposure to fenitroth-
ion among Australian eaters of cereals and
cereal products came close to this value.
This study involved the administration of
fenitrothion doses at 36 × and 72 × the
FAO/WHO ADI value over 4-day periods.
The previous pilot study suggested these doses
were likely to be well tolerated. Measurement
of the half-life of fenitrothion and its major
metabolite suggested a relatively short half-life
of 3 hr. Thus, a 4-day period of regular dosing
was considered sufficient to produce steady-
state blood concentrations close to those likely
after a more prolonged period of dosing.
Results of the toxicokinetic study indicate
fenitrothion is rapidly absorbed and extensively
metabolized in humans. The majority of each
dose was rapidly excreted in the form of MNP.
However, the AUC observed after 3 days of
dosing was approximately 3-fold greater than
that seen after the initial dose, raising the pos-
sibility that excretion is less rapid after the
initial dose. Further studies with a longer
duration of kinetic monitoring would be
needed to determine whether significant
pharmacokinetic accumulation is occurring.
The ﬁndings of rapid absorption and exten-
sive metabolism are in keeping with those
observed in various animal species (6,7). The
minimal suppression of plasma cholinesterase
at the doses administered suggests the present
ADI is likely to confer a substantial safety mar-
gin. Plasma cholinesterase is substantially more
sensitive to anticholinergic agents than red cell
cholinesterase, whereas the latter more closely
reﬂects the activity of cholinesterase enzymes
within the nervous system. Therefore, the
safety margin between the current ADI and the
levels exerting a toxic effect on nerve synapses is
likely to be even greater. The lack of symptoms
and the absence of abnormalities detected on
biochemical and hematologic monitoring also
support the likelihood that the present ADI
confers a substantial safety margin.
The results are also in keeping with a pre-
viously published human study. Nosal and
Hladka (8) reported results of a single-dose
study in which 24 volunteers ingested feni-
trothion in doses of 2.5–20 mg (equivalent
to 0.04–0.33 mg/kg body weight) (8).
Depression of plasma cholinesterase was
observed in only one subject whose activity
declined to 72% after a 20-mg dose. No
symptoms were reported, and levels returned
to normal within 24 hr.
Although the primary toxicity associated
with fenitrothion exposure is related to
acetylcholinesterase inhibition, there has also
been some concern about the endocrine and
reproductive toxicity, or more speciﬁcally, the
inhibitory effects on the human androgen
receptor (9). A recent study using HepG2
human hepatoma cells and male Sprague-
Dawley rats has demonstrated that fenitroth-
ion competitively antagonizes androgen
receptor activity in transfected cells and causes
regression of androgen-dependent tissue
weights in vivo (9). Researchers reported that
inhibition of androgen receptor function in
vivo occurred at a dose of fenitrothion that did
not signiﬁcantly alter acetylcholinesterase activ-
ity. These findings have not resulted in a
decrease in the ADI and were not considered
in this study, where we based the safety of feni-
trothion on its inhibition of cholinesterase.
In summary, these results suggest feni-
trothion is rapidly absorbed and extensively
metabolized after oral administration to
humans. The lack of signiﬁcant suppression of
plasma or red cell cholinesterase (and the
absence of symptoms or of abnormalities in
laboratory testing) after 3 days of dosing at a
level 72 × that of the ADI suggests the present
ADI confers a substantial margin of safety, at
least in relation to acute (ﬁrst dose) and suba-
cute effects of the agent. However, more pro-
longed repeat-dosing studies are required to
resolve the issue of accumulation.
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Table 3. Pharmacokinetic parameters of fenitrothion: dose 2 (0.36 mg/kg/day).
Cmax (ng/mL)a Tmax (hr)a AUC (ng/hr/mL)a t1/2 (hr)a
Day 1 2.2 ± 4.4 2.5 10.2 ± 12.0 2.5 ± 1.3
Day 4 8.5 ± 8.1 1.0 30.9 ± 21.5 3.6 ± 4.0
aValues derived by averaging individual measurements of subjects with sufﬁcient levels to enable calculation of the relevant
parameters.
Table 4. Excretion of MNP metabolite related to fenitrothion dose.
Dose 1 Dose 2
Day 1 Day 4 Day 1 Day 4
Mean MNP excretion (mg) 5.97 3.63 9.85 5.69
Fenitrothion equivalent (mg) 10.8 6.56a 17.8 10.3a
Mean oral fenitrothion dose (mg) 13 6.75 26.4 13.5
Percent excreted in 24 hr 83 97 67 76
aOnly the morning fenitrothion dose was given to subjects on day 4.